These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 17511926

  • 1. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 2. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 3. Biological agents in the treatment of psoriasis.
    Tzu J, Krulig E, Cardenas V, Kerdel FA.
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [Abstract] [Full Text] [Related]

  • 4. Update on the mechanisms and efficacy of biological therapies for psoriasis.
    Koo J, Khera P.
    J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 6. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 7. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH, Prinz J, Gottlieb AB.
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [Abstract] [Full Text] [Related]

  • 8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 9. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 Oct; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 11. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.
    Ned Tijdschr Geneeskd; 2006 May 13; 150(19):1065-70. PubMed ID: 16733982
    [Abstract] [Full Text] [Related]

  • 12. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE, Nunley K, Heffernan MP.
    J Am Acad Dermatol; 2007 Jan 13; 56(1):e55-79. PubMed ID: 17190618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM, Saini R.
    Cutis; 2003 Jan 13; 71(1):25-9. PubMed ID: 12553627
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug 13; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C.
    J Cutan Med Surg; 2006 Aug 13; 9 Suppl 1():18-25. PubMed ID: 16633860
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov 13; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.